生物学杂志

Journal of Biology ›› 2023, Vol. 40 ›› Issue (2): 1-.doi: 10.3969/j.issn.2095-1736.2023.02.001

    Next Articles

Discoidin domain receptor 1 (DDR1): a new drug target for solid tumors

SHU hang1, JIN Tengchuan2,3, WANG Hua1,4   

  1. 1. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China;
    2. Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230000, China;
    3. Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230000, China;
    4. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230000, China
  • Online:2023-04-18 Published:2023-04-18

PDF (PC)

32

Abstract: DDR1, a member of the discoidin domain receptor family (DDRs), is widely expressed in human normal tissues and is closely related to the genesis and development of tumors. Based on the structure and biological characteristics of DDR1, this paper reviews the research progress of DDR1 in tumor, expounds the effects of DDR1 on tumor cell proliferation, survival, migration, invasion, epithelial interstitial transformation, and cell metabolism, as well as the important role of DDR1 in tumor microenvironment, and summarizes the progress of anti-tumor drugs targeting DDR1. The study aims to provide theoretical basis and clinical reference for DDR1 as a new target for solid tumor therapy in the future.

Key words: discoidin domain receptor 1, tumor, signaling pathway, tumor microenvironment

CLC Number: